Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
Health Canada cautions against use of Sensipar in children
- Starting date:
- March 7, 2013
- Posting date:
- March 7, 2013
- Type of communication:
- Information Update
- Drugs, Affects children, pregnant or breast feeding women
- Source of recall:
- Health Canada
- Important Safety Information
- General Public
- Identification number:
- What you should do
- Report health or safety concerns
- Related AWRs
- Media enquiries
- Public enquiries
Following the death of a child enrolled in a clinical trial for the drug Sensipar in the United States, Health Canada is reminding healthcare professionals and consumers that Sensipar is not approved for use in patients under 18 years of age.
Sensipar (cinacalcet) is used for treating disorders of the parathyroid gland that result in high blood calcium levels.
Amgen, the manufacturer of Sensipar, recently halted all pediatric clinical trials of the drug after the death of a 14-year-old patient who developed very low blood calcium levels during a trial. It has not been determined whether Sensipar had a role in the patient's death. There have been no clinical trials of Sensipar involving children in Canada.
As indicated in the drug label, Sensipar is not approved for use in children. No adverse reactions to Sensipar involving a patient under 18 years of age have been reported to Health Canada. The risk of low blood calcium levels associated with the use of Sensipar is already part of the product labelling.
Health Canada is currently reviewing available safety information and will consider updating the labelling information, as appropriate.
What you should do
Patients with questions or concerns about their Sensipar treatment should speak to their healthcare professional.
Additional information for healthcare professionals
The Canadian drug label for Sensipar warns about the risk of hypocalcemia (low blood calcium levels) associated with its use. Healthcare professionals should carefully monitor patients for this risk. Symptoms of hypocalcemia include convulsions, irregular heartbeat, involuntary contraction of muscles and numbness (hands, feet, mouth, lips).
Report health or safety concerns
- Call toll-free at 1-866-234-2345
- Visit MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax